Face Video Competition

The final publication is available at Springer via http://dx.doi.org/10.1007/978-3-642-01793-3_73Person recognition using facial features, e.g., mug-shot images, has long been used in identity documents. However, due to the widespread use of web-cams and mobile devices embedded with a camera, it is now possible to realise facial video recognition, rather than resorting to just still images. In fact, facial video recognition offers many advantages over still image recognition; these include the potential of boosting the system accuracy and deterring spoof attacks. This paper presents the first known benchmarking effort of person identity verification using facial video data. The evaluation involves 18 systems submitted by seven academic institutes.The work of NPoh is supported by the advanced researcher fellowship PA0022121477of the Swiss NSF; NPoh, CHC and JK by the EU-funded Mobio project grant IST-214324; NPC and HF by the EPSRC grants EP/D056942 and EP/D054818; VS andNP by the Slovenian national research program P2-0250(C) Metrology and Biomet-ric System, the COST Action 2101 and FP7-217762 HIDE; and, AAS by the Dutch BRICKS/BSIK project.Poh, N.; Chan, C.; Kittler, J.; Marcel, S.; Mc Cool, C.; Rua, E.; Alba Castro, J.... (2009). Face Video Competition. En Advances in Biometrics: Third International Conference, ICB 2009, Alghero, Italy, June 2-5, 2009. Proceedings. 715-724. https://doi.org/10.1007/978-3-642-01793-3_73S715724Messer, K., Kittler, J., Sadeghi, M., Hamouz, M., Kostyn, A., Marcel, S., Bengio, S., Cardinaux, F., Sanderson, C., Poh, N., Rodriguez, Y., Kryszczuk, K., Czyz, J., Vandendorpe, L., Ng, J., Cheung, H., Tang, B.: Face authentication competition on the BANCA database. In: Zhang, D., Jain, A.K. (eds.) ICBA 2004. LNCS, vol. 3072, pp. 8–15. Springer, Heidelberg (2004)Messer, K., Kittler, J., Sadeghi, M., Hamouz, M., Kostin, A., Cardinaux, F., Marcel, S., Bengio, S., Sanderson, C., Poh, N., Rodriguez, Y., Czyz, J., Vandendorpe, L., McCool, C., Lowther, S., Sridharan, S., Chandran, V., Palacios, R.P., Vidal, E., Bai, L., Shen, L.-L., Wang, Y., Yueh-Hsuan, C., Liu, H.-C., Hung, Y.-P., Heinrichs, A., Muller, M., Tewes, A., vd Malsburg, C., Wurtz, R., Wang, Z., Xue, F., Ma, Y., Yang, Q., Fang, C., Ding, X., Lucey, S., Goss, R., Schneiderman, H.: Face authentication test on the BANCA database. In: Int’l. Conf. Pattern Recognition (ICPR), vol. 4, pp. 523–532 (2004)Phillips, P.J., Flynn, P.J., Scruggs, T., Bowyer, K.W., Chang, J., Hoffman, K., Marques, J., Min, J., Worek, W.: Overview of the Face Recognition Grand Challenge. In: IEEE Computer Society Conference on Computer Vision and Pattern Recognition, pp. 947–954 (2005)Bailly-Baillière, E., Bengio, S., Bimbot, F., Hamouz, M., Kittler, J., Marithoz, J., Matas, J., Messer, K., Popovici, V., Porée, F., Ruiz, B., Thiran, J.-P.: The BANCA Database and Evaluation Protocol. In: Kittler, J., Nixon, M.S. (eds.) AVBPA 2003. LNCS, vol. 2688. Springer, Heidelberg (2003)Turk, M., Pentland, A.: Eigenfaces for Recognition. Journal of Cognitive Neuroscience 3(1), 71–86 (1991)Martin, A., Doddington, G., Kamm, T., Ordowsk, M., Przybocki, M.: The DET Curve in Assessment of Detection Task Performance. In: Proc. Eurospeech 1997, Rhodes, pp. 1895–1898 (1997)Bengio, S., Marithoz, J.: The Expected Performance Curve: a New Assessment Measure for Person Authentication. In: The Speaker and Language Recognition Workshop (Odyssey), Toledo, pp. 279–284 (2004)Poh, N., Bengio, S.: Database, Protocol and Tools for Evaluating Score-Level Fusion Algorithms in Biometric Authentication. Pattern Recognition 39(2), 223–233 (2005)Martin, A., Przybocki, M., Campbell, J.P.: The NIST Speaker Recognition Evaluation Program, ch. 8. Springer, Heidelberg (2005

Coronary calcium mass scores measured by identical 64-slice MDCT scanners are comparable: a cardiac phantom study

To assess whether absolute mass scores are comparable or differ between identical 64-slice MDCT scanners of the same manufacturer and to compare absolute mass scores to the physical mass and between scan modes using a calcified phantom. A non-moving anthropomorphic phantom with nine calcifications of three sizes and three densities was scanned 30 times on three 64-slice MDCT scanners of manufacturer A and on three 64-slice MDCT scanners of manufacturer B in both sequential and spiral scan mode. The mean mass scores and mass score variabilities of seven calcifications were determined for all scanners; two non-detectable calcifications were omitted. It was analyzed whether identical scanners yielded similar or significantly different mass scores. Furthermore mass scores were compared to the physical mass and mass scores were compared between scan modes. The mass score calibration factor was determined for all scanners. Mass scores obtained on identical scanners were similar for almost all calcifications. Overall, mass score differences between the scanners were small ranging from 1.5 to 3.4% for the total mass scores, and most differences between scanners were observed for high density calcifications. Mass scores were significantly different from the physical mass for almost all calcifications and all scanners. In sequential mode the total physical mass (167.8 mg) was significantly overestimated (+2.3%) for 4 out of 6 scanners. In spiral mode a significant overestimation (+2.5%) was found for system B and a significant underestimation (−1.8%) for two scanners of system A. Mass scores were dependent on the scan mode, for manufacturer A scores were higher in sequential mode and for manufacturer B in spiral mode. For system A using spiral scan mode no differences were found between identical scanners, whereas a few differences were found using sequential mode. For system B the scan mode did not affect the number of different mass scores between identical scanners. Mass scores obtained in the same scan mode are comparable between identical 64-slice CT scanners and identical 64-slice CT scanners on different sites can be used in follow-up studies. Furthermore, for all systems significant differences were found between mass scores and the physical calcium mass; however, the differences were relatively small and consistent

Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study

Background: Treatment of pulmonary sarcoidosis is recommended in case of significant symptoms, impaired or deteriorating lung function. Evidence-based treatment recommendations are limited and largely based on expert opinion. Prednisone is currently the first-choice therapy and leads to short-term improvement of lung function. Unfortunately, prednisone often has side-effects and may be associated with impaired quality of life. Methotrexate is presently considered second-line therapy, and appears to have fewer side-effects. Objective: The primary objective of this trial is to investigate the effectiveness and tolerability of methotrexate as first-line therapy in patients with pulmonary sarcoidosis compared with prednisone. The primary endpoint of this study will be the change in hospital-measured Forced Vital Capacity (FVC) between baseline and 24 weeks. Secondary objectives are to gain more insights in response to therapy in individual patients by home spirometry and patient-reported outcomes. Blood biomarkers will be examined to find predictors of response to therapy, disease progression and chronicity, and to improve our understanding of the underlying disease mechanism. Methods/design: In this prospective, randomized, non-blinded, multi-center, non-inferiority trial, we plan to randomize 138 treatment-naïve patients with pulmonary sarcoidosis who are about to start treatment. Patients will be randomized in a 1:1 ratio to receive either prednisone or methotrexate in a predefined schedule for 24 weeks, after which they will be followed up in regular care for up to 2 years. Regular hospital visits will include pulmonary function assessment, completion of patient-reported outcomes, and blood withdrawal. Additionally, patients will be asked to perform weekly home spirometry, and record symptoms and side-effects via a home monitoring application for 24 weeks. Discussion: This study will be the first randomized controlled trial comparing first-line treatment of prednisone and methotrexate and provide valuable data on efficacy, safety, quality of life and biomarkers. If this study confirms the hypothesis that methotrexate is as effective as prednisone as first-line treatment for sarcoidosis but with fewer sideeffects, this will lead to improvement in care and initiate a change in practice. Furthermore, insights into the immunological mechanisms underlying sarcoidosis pathology might reveal new therapeutic targets

A compilation of charged-particle induced thermonuclear reaction rates

Low-energy cross section data for 86 charged-particle induced reactions involving light (1 less than or equal to Z less than or equal to 14), mostly stable, nuclei are compiled. The corresponding Maxwellian-averaged thermonuclear reaction rates of relevance in astrophysical plasmas at temperatures in the range from 10(6) K to 10(10) K are calculated. These evaluations assume either that the target nuclei are in their ground state, or that the target states are thermally populated following a Maxwell-Boltzmann distribution, except in some cases involving isomeric states. Adopted values complemented with lower and upper limits of the rates are presented in tabular form. Analytical approximations to the adopted rates, as well as to the inverse/direct rate ratios, are provided. (C) 1999 Elsevier Science B.V. All rights reserved

Forward pi^0 Production and Associated Transverse Energy Flow in Deep-Inelastic Scattering at HERA

Deep-inelastic positron-proton interactions at low values of Bjorken-x down to x \approx 4.10^-5 which give rise to high transverse momentum pi^0 mesons are studied with the H1 experiment at HERA. The inclusive cross section for pi^0 mesons produced at small angles with respect to the proton remnant (the forward region) is presented as a function of the transverse momentum and energy of the pi^0 and of the four-momentum transfer Q^2 and Bjorken-x. Measurements are also presented of the transverse energy flow in events containing a forward pi^0 meson. Hadronic final state calculations based on QCD models implementing different parton evolution schemes are confronted with the data.Comment: 27 pages, 8 figures and 3 table

Protocol for the CUPIDO trials; multicenter randomized controlled trials to assess the value of combining prolapse surgery and incontinence surgery in patients with genital prolapse and evident stress incontinence (CUPIDO I) and in patients with genital prolapse and occult stress incontinence (CUPIDO II)

Background: About 40% of all patients with genital prolapse report stress-incontinence. In about half of the 60% patients that do not report stress-incontinence, occult urinary stress-incontinence can be detected. In these patients stress-incontinence is masked due to kinking or compression of the urethra by the prolapse. In case surgical correction is indicated there are two strategies to manage patients with combined prolapse and (occult) stress incontinence. This strategy is either (i) a combination of prolapse surgery and stress-incontinence surgery or (ii) to correct the prolapse first and evaluate afterwards whether additional stress-incontinence surgery is indicated. The advantage of combining prolapse and stress-incontinence surgery is that only few patients report stress-incontinence following such combination. However, this combination has been associated with an increased risk on complications, of which the development of obstructive micturition symptoms, overactive bladder symptoms and bladder retention are the most important ones. Furthermore, combining two procedures may be unnecessary as performing only prolapse surgery may cure stress-incontinence In the randomized CUPIDO trials both strategies are compared in patients with prolapse and evident stress incontinence (CUPIDO I trial) and in patients with prolapse and occult stress incontinence (CUPIDO II trial). Methods/Design: The CUPIDO trials are two multicenter randomized controlled trials in which women with stress urinary incontinence (SUI) or occult stress urinary incontinence (OSUI) are randomized to prolapse surgery combined with anti incontinence surgery (concomitant surgery) or to prolapse surgery only. Patients with at least stage 2 POP are eligible, women with evident SUI are randomized in CUPIDO I. Patients without SUI are eligible for CUPIDO II and will have urodynamic evaluation or a standardized redression test. Women with OSUI are randomized, women without OSUI are followed up but not randomized. The primary outcome measure is absence of SUI twelve months after surgery. Furthermore, economic evaluations are conducted, and the effectiveness of urodynamic investigation is evaluated against a non-invasive way to determine SUI in women with POP. A total of 450 women will be included in the study

Depression, Anxiety and Glucose Metabolism in the General Dutch Population: The New Hoorn Study

BACKGROUND: There is a well recognized association between depression and diabetes. However, there is little empirical data about the prevalence of depressive symptoms and anxiety among different groups of glucose metabolism in population based samples. The aim of this study was to determine whether the prevalence of increased levels of depression and anxiety is different between patients with type 2 diabetes and subjects with impaired glucose metabolism (IGM) and normal glucose metabolism (NGM). METHODOLOGY/PRINCIPAL FINDINGS: Cross-sectional data from a population-based cohort study of 2667 residents, 1261 men and 1406 women aged 40-65 years from the Hoorn region, the Netherlands. Depressive symptoms and anxiety were measured using the Centre for Epidemiologic Studies Depression Scale (CES-D, score >or=16) and the Hospital Anxiety and Depression Scale--Anxiety Subscale (HADS-A, score >or=8), respectively. Glucose metabolism status was determined by oral glucose tolerance test. In the total study population the prevalence of depressive symptoms and anxiety for the NGM, IGM and type 2 diabetes were 12.5, 12.2 and 21.0% (P = 0.004) and 15.0, 15.3 and 19.9% (p = 0.216), respectively. In men, the prevalence of depressive symptoms was 7.7, 9.5 and 19.6% (p<0.001), and in women 16.4, 15.8 and 22.6 (p = 0.318), for participants with NGM, IGM and type 2 diabetes, respectively. Anxiety was not associated with glucose metabolism when stratified for sex. Intergroup differences (NGM vs. IGM and IGM vs. type 2 diabetes) revealed that higher prevalences of depressive symptoms are mainly manifested in participants with type 2 diabetes, and not in participants with IGM. CONCLUSIONS: Depressive symptoms, but not anxiety are associated with glucose metabolism. This association is mainly determined by a higher prevalence of depressive symptoms in participants with type 2 diabetes and not in participants with IGM